Cardiac Adverse Events in Patients With Chronic Lymphocytic Leukemia Treated With First-Line Ibrutinib-Venetoclax.
BACKGROUND Fixed-duration combination of ibrutinib and venetoclax (IV) has emerged as a highly effective first-line treatment for chronic lymphocytic leukemia (CLL). However, the cardiac safety profile of this regimen has not been comprehensively characterized. We conducted a systematic review and meta-analysis to eval...